Pharmacokinetics and Biochemical Efficacy of an α(1)-Proteinase Inhibitor (Aralast NP) in α(1)-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis

INTRODUCTION: Augmentation therapy with plasma-derived α(1)-proteinase inhibitor (A1PI) products is currently the only approved disease-specific therapy for α(1)-antitrypsin deficiency (AATD), a genetic disorder associated with decreased levels of A1PI. Systemic trough levels of A1PI in plasma or se...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhaoyang, Franke, Ryan M., Morris, Denise N., Yel, Leman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458804/
https://www.ncbi.nlm.nih.gov/pubmed/36001294
http://dx.doi.org/10.1007/s41030-022-00199-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458804/
https://www.ncbi.nlm.nih.gov/pubmed/36001294
http://dx.doi.org/10.1007/s41030-022-00199-4

Ejemplares similares